In this study, based on network pharmacology and functional enrichment analyses, 9 hub targets (CCL2, IL-10, PTGS2, TNF, MAPK1, IL-6, CXCL8, TP53, and VEGFA) and PI3K-Akt pathway were predicted as the potential target mechanisms for FHD treating NS. Here, AKT1 is linked to hypoalphalipoproteinemia, primary, 1.